ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "observation and registries"

  • Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting

    Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Daniela DiGuiseppe 2, Anne Gitte Loft 3, Manuel Pombo-Suarez 4, Herman Mann 5, Ziga Rotar 6, Florenzo Iannone 7, Tore Kvien 8, Maria José Santos 9, Kari K. Eklund 10, Bjorn Gudbjornsson 11, Catalin Codreanu 12, Sema Yılmaz 13, Johan Askling 14, Carlos Sánchez-Piedra 15, Karel Pavelka 5, Matija Tomsic 16, Fabrizio Conti 17, Joe Sexton 18, Helena Santos 19, Nina Trokovic 20, Thorvardur J Love 21, Ruxandra IONESCU 22, Yavuz Pehlivan 23, Michael J. Nissen 24, Gary Macfarlane 25, Irene van der Horst-Bruinsma 26, Stylianos Georgiadis 27, Lykke Midtbøll Ørnbjerg 28, Cecilie Heegaard Brahe 28, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 5Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 6UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 7Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 11Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 12Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 13Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, 14Karolinska Institutet, Stockholm, Sweden, 15Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 16Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 17Sapienza University of Rome, Rome, Italy, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20Helsinki University Central Hospital, Helsinki, Finland, 21Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 22SPITALUL CLINIC SFANTA MARIA, Bucharest, 23Uludağ University, Bursa, Turkey, 24University Hospital Geneva, Geneva, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 28Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…
  • Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting

    6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Johan Askling 2, Catalin Codreanu 3, Herman Mann 4, Anne Gitte Loft 5, Manuel Pombo-Suarez 6, Ziga Rotar 7, Tore Kvien 8, Maria José Santos 9, Anna Mari Hokkanen 10, Florenzo Iannone 11, Bjorn Gudbjornsson 12, Fatos Onen 13, Lennart Jacobsson 14, Ruxandra IONESCU 15, Karel Pavelka 4, Carlos Sánchez-Piedra 16, Matija Tomsic 17, Joe Sexton 18, Helena Santos 19, Jenny Österlund 20, Alberto Cauli 21, Arni Jon Geirsson 22, Servet Akar 23, Adrian Ciurea 24, Gareth Jones 25, Irene van der Horst-Bruinsma 26, Cecilie Heegaard Brahe 27, Stylianos Georgiadis 28, Lykke Midtbøll Ørnbjerg 27, Mikkel Østergaard 29 and Merete Lund Hetland 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Karolinska Institutet, Stockholm, Sweden, 3Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 6Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 7UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Helsinki University Hospital, Helsinki, Finland, 11Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, 15SPITALUL CLINIC SFANTA MARIA, Bucharest, 16Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 17Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, 21Universitá di Cagliari, Cagliari, Italy, 22Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 23Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 24University Hospital Zürich, Zürich, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 28DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 30DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology